Sponsor or institution

Clinical trials and research at Suzhou Suncadia Biopharmaceuticals Co., Ltd.

• 52Clinical trials
• 2Countries

Newest trials

All recruiting trials (52)

• SHR-4595 Injection in Advanced Solid Tumors: Safety, Tolerability, and Dosing in Phase 1

  This early-phase trial tests SHR-4595 injections to see if they are safe and tolerable for adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shenyang, Liaoning and 1 other locations · NCT07830199

• Trastuzumab plus bevacizumab vs bevacizumab alone as first-line maintenance therapy for ovarian cancer

  This trial tests whether adding trastuzumab to bevacizumab maintenance helps people with epithelial ovarian cancer after initial platinum-based therapy.

  Recruiting at 3 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT07779538

• SHR-9839 alone or with chemotherapy plus adebrelimab in advanced esophageal squamous cell cancer

  This trial tests SHR-9839 by itself or with chemotherapy and adebrelimab to see if it helps people with advanced ESCC.

  Recruiting at 2 sites Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07751341

• SHR-6914 in adults with prostate cancer

  A early-stage study tests SHR-6914 as a single therapy to see if it is safe and tolerable in adults with prostate cancer.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT07735377

• Shr-1501 plus BCG vs placebo plus BCG in high-risk papillary-only NMIBC

  This phase 3 trial tests whether SHR-1501 added to BCG helps people with high-risk papillary-only non-muscle-invasive bladder cancer compared to placebo with BCG.

  Recruiting at 2 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07726992

• Combination therapy for residual triple-negative breast cancer after neoadjuvant treatment

  This Phase 3 trial tests whether Trastuzumab Rezetecan plus Adebrelimab works better than the investigator’s choice in people with residual invasive triple-negative breast cancer after prior treatment.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07679360

• SHR-4685 safety in adults with solid tumors

  This study tests SHR-4685’s safety and how it behaves in the body for adults with advanced solid tumors.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · North Ryde, New South Wales and 5 other locations · NCT07676903

• SHR-A1811 plus chemotherapy and bevacizumab as first-line treatment for advanced colorectal cancer

  A first-line treatment test combines SHR-A1811 with chemotherapy and bevacizumab to see if it works better than standard therapy in adults with advanced colorectal cancer.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07676162

• SHR-3079 in B-cell non-Hodgkin lymphoma

  This small early study tests SHR-3079 in adults with B-cell non-Hodgkin lymphoma to see if it is safe and tolerable and to find a workable dose for future testing.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07661537

• SHR-5421 in Relapsed or Refractory Multiple Myeloma

  This phase 1 study tests SHR-5421 in adults with active, relapsed or refractory multiple myeloma to see if it is safe and how the body handles it.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07652281

• Testing SHR-1826 in locally advanced or metastatic non-small cell lung cancer

  This trial tests whether SHR-1826 given by IV every three weeks can help people with locally advanced or metastatic non-small cell lung cancer that has progressed after prior systemic therapy.

  Recruiting Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Jinan, Shandong · NCT07489716

• SHR-2524 plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma

  This trial tests whether SHR-2524 combined with bevacizumab is safe and tolerable as a first-line treatment for adults with advanced unresectable hepatocellular carcinoma.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Fuzhou, Fujian and 1 other locations · NCT07478302

• Adebrelimab plus SHR-8068 with chemoradiotherapy as perioperative care for resectable locally advanced rectal cancer.

  This trial will test whether adding two immunotherapy drugs (adebrelimab and SHR-8068) to chemoradiotherapy around the time of surgery helps people with resectable locally advanced rectal cancer.

  Recruiting at 2 sites Phase 2/3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Wuhan, Hubei and 1 other locations · NCT07454720

• SHR-A1904 for advanced biliary tract cancer after prior systemic treatment failure

  This trial will test whether the experimental drug SHR-A1904 can help people with advanced or metastatic biliary tract cancer whose prior systemic treatments failed and whose tumors express CLDN18.2.

  Recruiting at 2 sites Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07450976

• Shr-1501 plus BCG vs physician-chosen chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer

  This study tests whether SHR-1501 given with BCG works better than the doctor-selected chemotherapy for people with BCG-unresponsive non-muscle invasive bladder cancer.

  Recruiting at 2 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07424287

• SHR-A2102 versus investigator's choice chemotherapy for recurrent or metastatic cervical cancer after platinum and PD-(L)1 therapy

  This trial tests whether SHR-A2102 works better than standard chemotherapy for people with recurrent or metastatic cervical cancer whose disease progressed after platinum-based chemotherapy and PD-(L)1 inhibitors.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT07418749

• Single subcutaneous dose of SHR-1894 in healthy adults

  This trial will test a single under-the-skin (subcutaneous) dose of SHR-1894 in healthy adults to see if it is safe and how the body processes it.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Chengdu, Sichuan · NCT07414602

• SHR-A2102 plus adebrelimab versus platinum-based chemotherapy for advanced urothelial carcinoma

  This test compares SHR-A2102 combined with adebrelimab to gemcitabine with cisplatin or carboplatin in people with previously untreated locally advanced or metastatic urothelial carcinoma.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07393542

• SHR-4375 combined with other cancer treatments for advanced solid tumors

  This study tests whether adding SHR-4375 to other cancer therapies helps adults with advanced solid tumors who have not responded to standard treatments.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT07298772

• Subcutaneous SHR-A1811 injections for adults with solid tumors.

  This trial will test SHR-A1811 given under the skin to see if it is safe, tolerable, and how the body processes it in adults with measurable solid tumors.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT07275242

• SHR-8068 with Adebrelimab and other anti-tumor drugs for advanced renal cell carcinoma

  This trial will test whether adding SHR-8068 to Adebrelimab (with or without other anti-cancer drugs) helps people with advanced clear cell renal cell carcinoma.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07239596

• SHR-9839 (subcutaneous) with other anti-cancer therapies for advanced solid tumors

  This study tests SHR-9839 given under the skin together with other anti-cancer treatments in adults with advanced solid tumors to see if it is safe, tolerable, and helps control disease.

  Recruiting at 2 sites Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Nanjing, Jiangsu and 1 other locations · NCT07229638

• SHR-8068 with adebrelimab and platinum chemotherapy versus durvalumab with platinum chemotherapy for first-line advanced biliary tract cancer

  This trial tests whether SHR-8068 plus adebrelimab and platinum chemotherapy works better than durvalumab plus platinum chemotherapy as first treatment for people with advanced biliary tract cancer.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Hangzhou, Zhejiang · NCT07229625

• SHR-4298 Injection for Malignant Solid Tumors: a Phase I/II study

  This study tests SHR-4298 injections in adults with advanced solid tumors to see if it is safe, tolerable, and has signs of activity.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT07229612

• SHR-8068 with adebrelimab and chemotherapy versus tislelizumab with chemotherapy for first-line advanced or metastatic non-small cell lung cancer

  This trial will test whether SHR-8068 plus adebrelimab with platinum chemotherapy works better than tislelizumab with platinum chemotherapy as first treatment for adults with newly diagnosed advanced or metastatic non-small cell lung cancer.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Jinan, Shandong · NCT07170995

• SHR-7782 injection for advanced malignant tumors

  This phase 1 trial will test SHR-7782 injections in adults with advanced malignant tumors who have measurable disease and adequate organ function.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07123129

• SHR-A1811 with adebrelimab and chemotherapy for untreated advanced gastric or gastroesophageal junction adenocarcinoma

  This trial will test whether adding SHR-A1811 to adebrelimab and standard chemotherapy helps people with untreated, unresectable, or metastatic gastric or gastroesophageal junction adenocarcinoma respond better or live longer than current first-line treatments.

  Recruiting at 2 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shenyang, Liaoning and 1 other locations · NCT07118527

• SHR-A1811 plus SHR-1316 as first-line treatment for PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer

  This will test whether SHR-A1811 combined with SHR-1316 as first-line therapy helps people with PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer live longer without their cancer getting worse compared with toripalimab plus nab‑paclitaxel.

  Recruiting at 2 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07111832

• Adebrelimab with SHR-A1811/SHR-A1904 plus chemotherapy or with SHR-8068 for gastric and gastroesophageal-junction cancer

  This trial tests whether adding Adebrelimab to SHR-A1811 or SHR-A1904 plus chemotherapy, or combining Adebrelimab with SHR-8068, improves outcomes for adults newly diagnosed with gastric or gastroesophageal-junction cancer who have not yet received treatment.

  Recruiting at 2 sites Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shijiazhuang, Hebei and 1 other locations · NCT07110571

• SHR-4506 injection for adults with malignant tumors

  This trial will test whether SHR-4506 injection is safe and tolerable in adults with malignant tumors who have exhausted or cannot use standard treatments.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT07068932

• SHR-A2102 with adebrelimab, with or without other anti-cancer drugs, for recurrent or metastatic head and neck squamous cell carcinoma

  This tests whether SHR-A2102 combined with adebrelimab, with or without other anti-cancer therapies, is safe and helps adults with recurrent or metastatic head and neck squamous cell carcinoma.

  Recruiting at 2 sites Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Chongqing, Chongqing Municipality and 1 other locations · NCT07059221

• SHR-4849 combined with other cancer drugs for malignant solid tumors

  This study will test whether adding SHR-4849 to other cancer drugs is safe and can help adults with malignant solid tumors.

  Recruiting Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Jinan, Shandong · NCT07028281

• SHR-2017 injection for preventing bone events in people with solid tumors that have spread to bone

  We are testing whether SHR-2017 injection can prevent bone complications in adults whose solid tumors have spread to bone.

  Recruiting Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT07028268

• Evaluating SHR-3792 Injection for Advanced Solid Tumors

  This study is testing a new injection called SHR-3792 to see if it can safely help people with advanced solid tumors feel better and how much of it they should take.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Jinan, Shandong · NCT06907628

• SHR-A2102 plus adebrelimab for muscle-invasive bladder cancer

  This study tests whether injections of SHR-A2102 combined with adebrelimab help adults with non-metastatic muscle-invasive bladder cancer and in phase III compares the combo to standard gemcitabine plus cisplatin chemotherapy.

  Recruiting Phase 2/3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT06879145

• Evaluating SHR-1314 Injection for Active Non-radiographic Axial Spondyloarthritis

  This study is testing if an injection called SHR-1314 can help adults with active non-radiographic axial spondyloarthritis feel better compared to a placebo.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT06860750

• SHR-A1811 combination regimen for recurrent or metastatic cervical cancer

  This trial tests a combination that includes the investigational agent SHR-A1811 with other cancer drugs to see if it helps people with recurrent or metastatic cervical cancer.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT06859775

• Evaluating SHR-1826 for patients with non-small cell lung cancer

  This study is testing a new injectable treatment called SHR-1826 to see if it can help people with non-small cell lung cancer feel better compared to current options.

  Recruiting Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT06844474

• Combining SHR-A1811 with chemotherapy for recurrent ovarian cancer

  This study is testing a new treatment combining SHR-A1811 with chemotherapy to see if it helps people with recurrent ovarian cancer feel better and respond well to the therapy.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Wuhan, Hubei · NCT06840002

• Treatment of HER2-positive Biliary Tract Cancer with SHR-A1811

  This study is testing a new treatment called SHR-A1811 to see if it helps people with advanced HER2-positive biliary tract cancer feel better and live longer.

  Recruiting at 2 sites Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Harbin, Heilongjiang and 1 other locations · NCT06778031

• Evaluating SHR-4375 for patients with solid tumors

  This study is testing a new treatment called SHR-4375 to see if it can help people with advanced solid tumors who haven't had success with other therapies.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT06764628

• Evaluating SHR-1826 with other cancer therapies for lung cancer

  This study is testing if a new drug called SHR-1826, when combined with other cancer treatments, can help people with non-small cell lung cancer feel better and respond well to therapy.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT06754930

• Evaluating SHR-1681 for patients with advanced solid tumors

  This study is testing a new injection called SHR-1681 to see if it can safely help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT06737731

• Using SHR-1826 with other treatments for advanced solid tumors

  This study is testing if a new treatment called SHR-1826, used with other cancer therapies, can help people with advanced solid tumors feel better and manage their disease.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT06703177

• Evaluating SHR-3276 for patients with advanced malignant tumors

  This study is testing a new treatment called SHR-3276 to see if it can help people with advanced solid tumors who have run out of other treatment options.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Chongqing, Chongqing Municipality · NCT06643754

• Treatment for advanced liver cancer using new drug combinations

  This study is testing whether a new combination of drugs can help people with advanced liver cancer live longer and feel better compared to another treatment option.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Hefei, Anhui · NCT06618664

• Evaluating SHR-3821 injection for advanced solid tumors

  This study is testing a new injection called SHR-3821 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Chengdu, Sichuan · NCT06618651

• Evaluating SHR-9539 for treating multiple myeloma

  This study is testing a new injection called SHR-9539 to see if it can safely help people with multiple myeloma feel better and manage their disease.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Chengdu, Sichuan · NCT06484777

• Evaluating SHR-4849 for Advanced Solid Tumors

  This study is testing a new injection called SHR-4849 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Jilin City, Changchun · NCT06443489

• New treatment for ovarian cancer that doesn't respond to platinum-based therapies

  This study is testing a new treatment called SHR-A1921 to see if it works better than standard chemotherapy for people with ovarian cancer that doesn't respond to platinum-based therapies.

  Recruiting at 2 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT06394492

• Testing SHR-1826 in patients with advanced solid tumors

  This study is testing a new drug called SHR-1826 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT06094556

• Combining SHR-A1811 with chemo and immunotherapy for advanced HER2-expressing stomach and gastroesophageal junction cancer

  This trial will test whether combining SHR-A1811 with chemotherapy and/or immunotherapy helps adults with advanced or metastatic HER2-expressing stomach or gastroesophageal junction cancer.

  Recruiting Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT05671822

Quick answers

How many clinical trials run by Suzhou Suncadia Biopharmaceuticals Co., Ltd. are recruiting right now?

52, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (52 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 15, Phase 3: 14, Phase 1/2: 12, Phase 2: 9. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →